Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 101–200 of 1,001
Dror, E., Dalmas, E., Meier, D. T., Wueest, S., Thévenet, J., Thienel, C., Timper, K., Nordmann, T. M., Traub, S., Schulze, F., et al. (2017) · Nature Immunology · doi:10.1038/ni.3659 · Cited by 394
Self-citationThe role of macrophages in obesity-associated islet inflammation and β-cell abnormalities
Ying, W., Fu, W., Lee, Y. S., & Olefsky, J. M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0286-3 · Cited by 391
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
“Targeting inflammation in AMI ( Figure 1 , area hatched in blue, ‘Baseline inflammation’) depends in part on the control of traditional cardiovascular risk factors such as dyslipi-daemia and diabetes, 95 as well as other comorbidities, particularly chronic inflammatory diseases.”
BackgroundSustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
“At baseline, and at 13 and 52 weeks, beta-cell secretory function was assessed by the fasting PI/I ratio and by a 2-hour oral glucose-tolerance test directly followed by a 12-minute intravenous glucose, glucagon and arginine stimulation test as described previously (16).”
BackgroundMethodResultInfluentialSelf-citationde Zoete, M. R., Palm, N. W., Zhu, S., & Flavell, R. A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016287 · Cited by 379
Solomon, D. H. (2011) · JAMA · doi:10.1001/jama.2011.878 · Cited by 393
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 389
Mitochondria: diversity in the regulation of the NLRP3 inflammasome
Gurung, P., Lukens, J. R., & Kanneganti, T.-D. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.11.008 · Cited by 393
Regulation of Obesity-Related Insulin Resistance with Gut Anti-inflammatory Agents
Luck, H., Tsai, S., Chung, J., Clemente-Casares, X., Ghazarian, M., Revelo, X. S., Lei, H., Luk, C. T., Shi, S. Y., Surendra, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.03.001 · Cited by 368
Jourdan, T., Godlewski, G., Cinar, R., Bertola, A., Szanda, G., Liu, J., Tam, J., Han, T., Mukhopadhyay, B., Skarulis, M. C., et al. (2013) · Nature Medicine · doi:10.1038/nm.3265 · Cited by 388
The IL-1 family of cytokines and receptors in rheumatic diseases
Dinarello, C. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0277-8 · Cited by 366
Diabetes Treatment — Bridging the Divide
Rother, K. I. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078030 · Cited by 370
Inflammation as a Link between Obesity and Metabolic Syndrome
Emanuela, F., Grazia, M., Marco, D. R., Maria Paola, L., Giorgio, F., & Marco, B. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/476380 · Cited by 357
Islet inflammation in type 2 diabetes and physiology
Eguchi, K., & Nagai, R. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88877 · Cited by 361
Abbate, A., Salloum, F. N., Vecile, E., Das, A., Hoke, N. N., Straino, S., Biondi-Zoccai, G. G. L., Houser, J.-E., Qureshi, I. Z., Ownby, E. D., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.740233 · Cited by 360
Böni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D. T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J. A., Schuit, F. C., et al. (2009) · Endocrinology · doi:10.1210/en.2009-0543 · Cited by 339
Self-citationSchwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329
Inflammation in End-Stage Renal Disease-What Have We Learned in 10 Years?
Carrero, J. J., & Stenvinkel, P. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00784.x · Cited by 354
Chronic tissue inflammation and metabolic disease
Lee, Y. S., & Olefsky, J. (2021) · Genes & Development · doi:10.1101/gad.346312.120 · Cited by 335
IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
Ehses, J. A., Lacraz, G., Giroix, M.-H., Schmidlin, F., Coulaud, J., Kassis, N., Irminger, J.-C., Kergoat, M., Portha, B., Homo-Delarche, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810087106 · Cited by 347
Self-citationThe Inflammasomes in Kidney Disease
Anders, H.-J., & Muruve, D. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080798 · Cited by 351
Islet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334
Self-citationPathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction
Solinas, G., & Karin, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-151340 · Cited by 347
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Self-citationThe role of interleukins in insulin resistance and type 2 diabetes mellitus
Fève, B., & Bastard, J.-P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.62 · Cited by 343
Adipose tissue-resident immune cells: key players in immunometabolism
Schipper, H. S., Prakken, B., Kalkhoven, E., & Boes, M. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.011 · Cited by 342
Islet Inflammation Impairs the Pancreatic β-Cell in Type 2 Diabetes
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., & Ehses, J. A. (2009) · Physiology · doi:10.1152/physiol.00032.2009 · Cited by 330
Self-citationInflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
Self-citationRole of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
Self-citationInterleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice
Miller, A. M., Asquith, D. L., Hueber, A. J., Anderson, L. A., Holmes, W. M., McKenzie, A. N., Xu, D., Sattar, N., McInnes, I. B., & Liew, F. Y. (2010) · Circulation Research · doi:10.1161/circresaha.110.218867 · Cited by 324
Handschin, C., Choi, C. S., Chin, S., Kim, S., Kawamori, D., Kurpad, A. J., Neubauer, N., Hu, J., Mootha, V. K., Kim, Y.-B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31785 · Cited by 335
Kelly, B., Tannahill, G. M., Murphy, M. P., & O'Neill, L. A. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662114 · Cited by 334
Tzanavari, T., Giannogonas, P., & Karalis, K. P. (2010) · Current Directions in Autoimmunity · doi:10.1159/000289203 · Cited by 322
The IL-1β phenomena in neuroinflammatory diseases
Mendiola, A. S., & Cardona, A. E. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1732-9 · Cited by 303
Böni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., & Donath, M. Y. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0396 · Cited by 320
Self-citationLTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes
Li, P., Oh, D. Y., Bandyopadhyay, G., Lagakos, W. S., Talukdar, S., Osborn, O., Johnson, A., Chung, H., Mayoral, R., Maris, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3800 · Cited by 315
Mechanisms of Inflammatory Responses in Obese Adipose Tissue
Sun, S., Ji, Y., Kersten, S., & Qi, L. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071811-150623 · Cited by 306
McColl, B. W., Rothwell, N. J., & Allan, S. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2674-08.2008 · Cited by 314
Mirza, R. E., Fang, M. M., Weinheimer-Haus, E. M., Ennis, W. J., & Koh, T. J. (2014) · Diabetes · doi:10.2337/db13-0927 · Cited by 319
The role of inflammasomes in kidney disease
Komada, T., & Muruve, D. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0158-z · Cited by 304
Minireview: Inflammation and Obesity Pathogenesis: The Hypothalamus Heats Up
Thaler, J. P., & Schwartz, M. W. (2010) · Endocrinology · doi:10.1210/en.2010-0336 · Cited by 313
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
“There are case reports of anakinra treatment for myocarditis in patients non-responsive to anti-IL-6 (Waghmare et al., 2015).”
BackgroundCell death and inflammation during obesity: “Know my methods, WAT(son)”
Hildebrandt, X., Ibrahim, M., & Peltzer, N. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-022-01062-4 · Cited by 277
Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance
Li, P., Liu, S., Lu, M., Bandyopadhyay, G., Oh, D., Imamura, T., Johnson, A. M. F., Sears, D., Shen, Z., Cui, B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.025 · Cited by 297
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, H., Pham, C. T., van der Meer, J. W. M., Dinarello, C. A., & van den Berg, W. B. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25006 · Cited by 296
Mitochondria: Sovereign of inflammation?
Tschopp, J. (2011) · European Journal of Immunology · doi:10.1002/eji.201141436 · Cited by 292
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
Rigamonti, E., Chinetti-Gbaguidi, G., & Staels, B. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158998 · Cited by 293
Focus on the Role of NLRP3 Inflammasome in Diseases
Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., & Di Paola, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124223 · Cited by 290
“Clinical analysis displays that an anti-IL-1β antibody and IL-1 receptor antagonist (IL-1RA) ameliorated β-cell function and glucose control levels [52,53].”
BackgroundThe global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation
Kolb, H., & Mandrup-Poulsen, T. (2010) · Diabetologia · doi:10.1007/s00125-009-1573-7 · Cited by 292
Self-citationEffects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H., Solinger, A. M., Mandrup-Poulsen, T., Dinarello, C. A., & Donath, M. Y. (2012) · Diabetes Care · doi:10.2337/dc11-2219 · Cited by 294
Self-citationObese adipocytes show ultrastructural features of stressed cells and die of pyroptosis
Giordano, A., Murano, I., Mondini, E., Perugini, J., Smorlesi, A., Severi, I., Barazzoni, R., Scherer, P. E., & Cinti, S. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m038638 · Cited by 297
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 294
Hocking, S., Samocha-Bonet, D., Milner, K.-L., Greenfield, J. R., & Chisholm, D. J. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1041 · Cited by 276
Moon, J.-S., Nakahira, K., Chung, K.-P., DeNicola, G. M., Koo, M. J., Pabón, M. A., Rooney, K. T., Yoon, J.-H., Ryter, S. W., Stout-Delgado, H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4153 · Cited by 291
RetractedInflammatory lipid mediators in adipocyte function and obesity
Iyer, A., Fairlie, D. P., Prins, J. B., Hammock, B. D., & Brown, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.264 · Cited by 285
Rodríguez, A., Ezquerro, S., Méndez-Giménez, L., Becerril, S., & Frühbeck, G. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00297.2015 · Cited by 282
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Innate Immune Recognition in Infectious and Noninfectious Diseases of the Lung
Opitz, B., van Laak, V., Eitel, J., & Suttorp, N. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200909-1427so · Cited by 274
Gut microbiota influence in type 2 diabetes mellitus (T2DM)
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00446-0 · Cited by 270
Role of the Inflammasome in Liver Disease
de Carvalho Ribeiro, M., & Szabo, G. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 277
Macrophages, Chronic Inflammation, and Insulin Resistance
Li, H., Meng, Y., He, S., Tan, X., Zhang, Y., Zhang, X., Wang, L., & Zheng, W. (2022) · Cells · doi:10.3390/cells11193001 · Cited by 264
Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review
Rheinheimer, J., de Souza, B. M., Cardoso, N. S., Bauer, A. C., & Crispim, D. (2017) · Metabolism · doi:10.1016/j.metabol.2017.06.002 · Cited by 273
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Cytokines and abnormal glucose and lipid metabolism
Shi, J., Fan, J., Su, Q., & Yang, Z. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00703 · Cited by 282
“Emerging clinical studies showed that IL-1 receptor antagonist (anakinra) and IL1β-specific antibody (gevokizumab, canakinumab, LY2189102) treatment improved glucose metabolism and insulin secretion in patients with T2D (61, 83).”
BackgroundSensing damage by the NLRP3 inflammasome
Leemans, J. C., Cassel, S. L., & Sutterwala, F. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01043.x · Cited by 281
Netrin-1 promotes adipose tissue macrophage retention and insulin resistance in obesity
Ramkhelawon, B., Hennessy, E. J., Ménager, M., Ray, T. D., Sheedy, F. J., Hutchison, S., Wanschel, A., Oldebeken, S., Geoffrion, M., Spiro, W., et al. (2014) · Nature Medicine · doi:10.1038/nm.3467 · Cited by 257
Obesity-induced Insulin Resistance and Hyperglycemia: Etiologic Factors and Molecular Mechanisms
Martyn, J. A. J., Kaneki, M., Yasuhara, S., Warner, D. S., & Warner, M. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181799d45 · Cited by 265
Ren, Y., Zhao, H., Yin, C., Lan, X., Wu, L., Du, X., Griffiths, H. R., & Gao, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.873699 · Cited by 244
IL‐1: Discoveries, controversies and future directions
Dinarello, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040319 · Cited by 268
The Inflammasome Puts Obesity in the Danger Zone
Stienstra, R., Tack, C. J., Kanneganti, T.-D., Joosten, L. A. B., & Netea, M. G. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.011 · Cited by 271
“Conversely, blockade of excessive IL-1 signaling in subjects with type 2 diabetes improves glycemic control and b cell function while reducing markers of systemic inflammation (Larsen et al., 2007).”
BackgroundInfluentialAdipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance?
Blüher, M. (2016) · Clinical Science · doi:10.1042/cs20160005 · Cited by 262
Chronic Inflammation Links Cardiovascular, Metabolic and Renal Diseases
Manabe, I. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-1184 · Cited by 263
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species
Wei, Y., Chen, K., Whaley-Connell, A. T., Stump, C. S., Ibdah, J. A., & Sowers, J. R. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00561.2007 · Cited by 258
Interleukin-6 regulates pancreatic α-cell mass expansion
Ellingsgaard, H., Ehses, J. A., Hammar, E. B., Van Lommel, L., Quintens, R., Martens, G., Kerr-Conte, J., Pattou, F., Berney, T., Pipeleers, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801059105 · Cited by 269
Self-citationBallak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., & van Diepen, J. A. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.005 · Cited by 255
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
“Indeed, anakinra treatment of patients with type 2 diabetes over 3 months improved glycaemic indexes and insulin secretio”
BackgroundHistone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus
Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., & Mandrup-Poulsen, T. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00021 · Cited by 261
Self-citationHasnain, S. Z., Borg, D. J., Harcourt, B. E., Tong, H., Sheng, Y. H., Ng, C. P., Das, I., Wang, R., Chen, A. C.-H., Loudovaris, T., et al. (2014) · Nature Medicine · doi:10.1038/nm.3705 · Cited by 263
Samavati, L., Rastogi, R., Du, W., Hüttemann, M., Fite, A., & Franchi, L. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.018 · Cited by 256
Glutamine Metabolism in Macrophages: A Novel Target for Obesity/Type 2 Diabetes
Ren, W., Xia, Y., Chen, S., Wu, G., Bazer, F. W., Zhou, B., Tan, B., Zhu, G., Deng, J., & Yin, Y. (2019) · Advances in Nutrition · doi:10.1093/advances/nmy084 · Cited by 252
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
Exercise and type 2 diabetes: focus on metabolism and inflammation
Karstoft, K., & Pedersen, B. K. (2016) · Immunology & Cell Biology · doi:10.1038/icb.2015.101 · Cited by 260
Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases
Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-017-0663-9 · Cited by 258
Inflammation and resolution in obesity
Soták, M., Clark, M., Suur, B. E., & Börgeson, E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01047-y · Cited by 198
Targeting the pancreatic β-cell to treat diabetes
Vetere, A., Choudhary, A., Burns, S. M., & Wagner, B. K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4231 · Cited by 252
Zeng, C., Shi, X., Zhang, B., Liu, H., Zhang, L., Ding, W., & Zhao, Y. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0816-5 · Cited by 245
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Dalmas, E., Venteclef, N., Caer, C., Poitou, C., Cremer, I., Aron-Wisnewsky, J., Lacroix-Desmazes, S., Bayry, J., Kaveri, S. V., Clément, K., et al. (2014) · Diabetes · doi:10.2337/db13-1511 · Cited by 240
Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review
Wali, J. A., Jarzebska, N., Raubenheimer, D., Simpson, S. J., Rodionov, R. N., & O’Sullivan, J. F. (2020) · Nutrients · doi:10.3390/nu12051505 · Cited by 235
Esser, N., Paquot, N., & Scheen, A. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.974804 · Cited by 250
Implication of inflammatory signaling pathways in obesity-induced insulin resistance
Tanti, J.-F., Ceppo, F., Jager, J., & Berthou, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00181 · Cited by 239
“Pharmacological inhibition of IL-1β signaling by the IL-1 receptor antagonist anakinra, mitigates inflammation, and improves glycemic control in type 2 diabetic patients (Larsen et al., 2007).”
BackgroundTilg, H., & Moschen, A. R. (2008) · Clinical Science · doi:10.1042/cs20070196 · Cited by 252
Salicylate (Salsalate) in Patients With Type 2 Diabetes: A Randomized Trial
Goldfine, A. B., Fonseca, V., Jablonski, K. A., Chen, Y.-D. I., Tipton, L., Staten, M. A., & Shoelson, S. E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-1-201307020-00003 · Cited by 251
Natural history of β-cell adaptation and failure in type 2 diabetes
Alejandro, E. U., Gregg, B., Blandino-Rosano, M., Cras-Méneur, C., & Bernal-Mizrachi, E. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.002 · Cited by 232
Metabonomic, transcriptomic, and genomic variation of a population cohort
Inouye, M., Kettunen, J., Soininen, P., Silander, K., Ripatti, S., Kumpula, L. S., Hämäläinen, E., Jousilahti, P., Kangas, A. J., Männistö, S., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.93 · Cited by 250
Latent Autoimmune Diabetes in Adults
Naik, R. G., Brooks-Worrell, B. M., & Palmer, J. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1120 · Cited by 249
Inflammation, Cytokines and Insulin Resistance: A Clinical Perspective
Wieser, V., Moschen, A. R., & Tilg, H. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0210-1 · Cited by 241
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.